Business Description
Veradermics Inc
NAICS : 325412
SIC : 2836
ISIN : US9229671048
Total Employee Number:
21Description
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 97699.25 | |||||
Equity-to-Asset | 0.98 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.34 | |||||
9-Day RSI | 42.88 | |||||
14-Day RSI | 46.37 | |||||
3-1 Month Momentum % | 26.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 59.12 | |||||
Quick Ratio | 59.12 | |||||
Cash Ratio | 58.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -84.81 | |||||
ROA % | -25.89 | |||||
ROIC % | -4966.8 | |||||
ROC (Joel Greenblatt) % | -21453.54 | |||||
ROCE % | -28.27 | |||||
Moat Score | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 10.73 | |||||
Price-to-Tangible-Book | 10.73 | |||||
EV-to-EBIT | -83.35 | |||||
EV-to-EBITDA | -83.35 | |||||
EV-to-FCF | -95.94 | |||||
| Price-to-Net-Current-Asset-Value | 10.74 | |||||
| Price-to-Net-Cash | 10.91 | |||||
Earnings Yield (Greenblatt) % | -1.2 | |||||
FCF Yield % | -0.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:MANE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Veradermics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.943 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 46.37 | ||
| 14-Day ATR ($) | 10.169476 | ||
| 20-Day SMA ($) | 117.1775 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 32 - 131.2399 | ||
| Shares Outstanding (Mil) | 41.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Veradermics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Veradermics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-30 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 41 days | ||
| General meeting for 2026 | 2026-07-20 | 111.32 (+2.59%) | ||
| Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females | 2026-07-15 08:00 | 110.17 (-0.78%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 14:00 | 91.69 (-8.42%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 15:10 | 98.18 (-3.28%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 108.13 (+2.98%) | ||
| Study 302 Phase 2/3 Topline Results | 2026-04-27 08:00 | 67.84 (-1.68%) | ||
| Annual report for 2025 | 2026-03-30 | 65.53 (-2.21%) |
Show
Entries
Veradermics Inc Frequently Asked Questions
What is Veradermics Inc(MANE)'s stock price today?
The current price of MANE is $112.22. The 52 week high of MANE is $131.24 and 52 week low is $32.00.
When is next earnings date of Veradermics Inc(MANE)?
The next earnings date of Veradermics Inc(MANE) is 2026-08-31 Est..
Does Veradermics Inc(MANE) pay dividends? If so, how much?
Veradermics Inc(MANE) does not pay dividend.
Guru Commentaries on NYSE:MANE
No articles.
Press Release
Articles on Veradermics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers